J
Joan H. Schiller
Researcher at University of Wisconsin-Madison
Publications - 160
Citations - 29240
Joan H. Schiller is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 156 publications receiving 27937 citations. Previous affiliations of Joan H. Schiller include University of Texas Southwestern Medical Center.
Papers
More filters
Journal Article
Biological and Clinical Effects of the Combination of β- and γ-Interferons Administered as a 5-Day Continuous Infusion
Joan H. Schiller,Barry E. Storer,Patricia L. Witt,Beth E. Nelson,Raymond R. Brown,Michel A. Horisberger,Sidney E. Grossberg,Ernest C. Borden +7 more
TL;DR: It is concluded that tolerable doses of IFN-β andIFN-γ do not result in serum IFN levels which produce significant synergistic antiproliferative responses in vitro, and, unless higher doses can be achieved, combinations of IFn- β and IFN -γ are unlikely to have significant therapeutic activity.
Journal ArticleDOI
Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504)
Suresh S. Ramalingam,Ju Whei Lee,Chandra P. Belani,Seena C. Aisner,Jill M. Kolesar,Craig Howe,Mario R. Velasco,Joan H. Schiller +7 more
TL;DR: Cetuximab was associated with modest efficacy in patients with advanced BAC, despite a low response rate, and EGFR and KRAS mutations were not predictive of response to cetUXimab.
Journal ArticleDOI
O-125 ECOG 2597: Phase III study of induction chemotherapy followed by standard thoracic radiotherapy (STD TRT) vs hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A & B non-small cell lung cancer
Chandra P. Belani,Wei Wang,David H. Johnson,Henry N. Wagner,Joan H. Schiller,Michael Veeder,Minesh P. Mehta +6 more
Journal Article
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor
Joan H. Schiller,Barry E. Storer,Kendra D. Tutsch,Rhoda Z. Arzoomanian,D. Alberti,C. Feierabend,David R. Spriggs +6 more
TL;DR: The maximum tolerated dose of paclitaxel administered as a 3-hour infusion was 210 mg/m2 without G-CSF and 250 mg/ m2 with G- CSF, and the dose-limiting toxicity was myelosuppression and peripheral neuropathy, both of which appeared to be dose related and somewhat cumulative.
Journal ArticleDOI
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
Navneet Singh,Sarah Temin,Sherman Baker,Elizabeth Blanchard,Julie R. Brahmer,Paul Celano,Narjust Duma,Peter M. Elias,Ivy B. Elkins,Rami Y. Haddad,Paul J. Hesketh,Dharamvir Jain,David W. Johnson,Natasha B. Leighl,Hirva Mamdani,Gregory A. Masters,Pamela R Moffitt,Tanyanika Phillips,Gregory J. Riely,Andrew G. Robinson,Rafael Rosell,Joan H. Schiller,Bryan J. Schneider,David Spiegel,Ishmael Jaiyesimi +24 more
TL;DR: This guideline update reflects changes in evidence since the previous update and is designed to provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non–small-cell lung cancer without driver alterations.